Search

Displaying results 3801 - 3810 of 7059 in total
  1. Drug

    Glovadalen

    go.drugbank.com/drugs/DB21709
    Investigational

    Glovadalen has a monoisotopic molecular weight of 475.14 Da. … Glovadalen is a small molecule drug.

  2. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    [L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724] … Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.

  3. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da. … Vabametkib is a small molecule drug.

  5. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    FDA-approved therapy for this condition. … In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

  6. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime. … of basal insulin over 42 hours with a low peak: trough ratio.

  7. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    [A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    [L31453] Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de … (1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>).

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  10. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    Tasurgratinib has a monoisotopic molecular weight of 587.27 Da. … Tasurgratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor.